Not Yet RecruitingPhase 3

Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines

South Korea324 participantsStarted 2025-07-15

Plain-language summary

To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines

Who can participate

Age range19 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Subjects with a facial wrinkle scale (FWS) score of ≥2 (moderate) for glabellar lines at maximum frown in the investigator's on-site assessment at screening Exclusion Criteria: \- Subjects with glabellar lines that cannot sufficiently be improved by physical attempts, e.g., glabellar lines not flattened by hand, in the judgment of the investigator

What they're measuring

Percentage of subjects with glabellar line improvement* rate at maximum frown based on the investigator's on-site assessment at 4 weeks after IP administration

Timeframe: At 4 weeks after IP administration

Trial details

NCT IDNCT07013279

SponsorDaewoong Pharmaceutical Co. LTD.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-12-31

View on ClinicalTrials.gov More Glabellar Lines trials